The hope is that the data in this paper and subsequent studies that further optimize the formulation to add an additional non-mucin penetrating depot of niclosamide that can nevertheless dissolve, perhaps combined with mucin-binding polymers that have been shown to also limit viral entry into cells (Bentley and Stanton 2021), will attract the right partners (governments, infectious disease institutes, and even companies) to take this forward and provide a preventative and early treatment option throughout the world. Here, MUC5AC is linked to infectious disease.